Meropenem is a carbapenem antibiotic for parenteral use. It is structurally similar to imipenem but is stable to human dehydropeptidase-1 (DHP-1). It shows potent bactericidal activity against a broad spectrum of Gram-positive and Gram-negative, aerobic and anaerobic bacteria as it can penetrates bacterial cell wall excellently, it has high level of stability to all serine ?-lactamases and it has marked affinity for the Penicillin Binding Proteins (PBPs).
Specbac IV Injection or Infusion
(in Injection form)
The dosage and duration of therapy should be established depending on type and severity of infection and the condition of the patient. The recommended daily dosage of adult is as follows:
Pneumonias, Urinary tract infections, gynaecological infections such as endometritis and pelvic inflammatory disease; skin and skin structure infections: Meropenem 500 mg IV every 8 hours
Nosocomial pneumonias, peritonitis, presumed infections in neutropenic patients and septicaemia: Meropenem 1 g IV every 8 hours
Meningitis: Meropenem 2 g IV every 8 hours
Cystic fibrosis: Meropenem IV up to 2 g every 8 hours
Use in children:
Children 0 to 3 months: Efficacy and tolerability in children under 3 months old have not been established; therefore Meropenem is not recommended.
For children over 3 months to 12 years of age: The recommended dose of Meropenem IV is 10 to 20 mg/kg every 8 hours depending on type and severity of infection, susceptibility of the pathogen and the condition of the patient.
For children aged 4 to 18 years with cystic fibrosis: The doses ranging of Meropenem IV is 25 to 40 mg/kg every 8 hours.
In children 50 kg weight: Adult dosage should be used.
In meningitis: The recommended dose of Meropenem IV is 40 mg/kg every 8 hours.
There is no experience in children with hepatic or renal impairment.
Elderly patients: No dosage adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.
Manufacturer: Square Pharmaceutical Ltd.